Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.84 USD | +1.66% | +1.66% | +44.88% |
May. 21 | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
May. 16 | Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.88% | 13.23M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.23% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating